Cejuela, M.; Gil-Torralvo, A.; Castilla, M.Á.; Domínguez-Cejudo, M.Á.; Falcón, A.; Benavent, M.; Molina-Pinelo, S.; Ruiz-Borrego, M.; Salvador Bofill, J.
Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer. Int. J. Mol. Sci. 2023, 24, 8488.
https://doi.org/10.3390/ijms24108488
AMA Style
Cejuela M, Gil-Torralvo A, Castilla MÁ, Domínguez-Cejudo MÁ, Falcón A, Benavent M, Molina-Pinelo S, Ruiz-Borrego M, Salvador Bofill J.
Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer. International Journal of Molecular Sciences. 2023; 24(10):8488.
https://doi.org/10.3390/ijms24108488
Chicago/Turabian Style
Cejuela, Mónica, Ana Gil-Torralvo, M. Ángeles Castilla, M. Ángeles Domínguez-Cejudo, Alejandro Falcón, Marta Benavent, Sonia Molina-Pinelo, Manuel Ruiz-Borrego, and Javier Salvador Bofill.
2023. "Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer" International Journal of Molecular Sciences 24, no. 10: 8488.
https://doi.org/10.3390/ijms24108488
APA Style
Cejuela, M., Gil-Torralvo, A., Castilla, M. Á., Domínguez-Cejudo, M. Á., Falcón, A., Benavent, M., Molina-Pinelo, S., Ruiz-Borrego, M., & Salvador Bofill, J.
(2023). Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer. International Journal of Molecular Sciences, 24(10), 8488.
https://doi.org/10.3390/ijms24108488
